Trial intelligence / Profile preview

Phase II open-label multicenter study of BEBT-109 in EGFR exon 20 insertion-mutated advanced or metastatic non-small cell lung cancer

CTR20213409Phase 2Active

Sponsor

BeBetter Med

Start

Apr 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1